Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Plewes, Katherine ^a   Royakkers, Annick A ^b,c   Hanson, Josh ^a,d   Hasan, Md Mahtab Uddin ^e   Alam, Shamsul ^e   Ghose, Aniruddha ^e   Maude, Richard J ^a   Stassen, Pauline M ^c   Charunwatthana, Prakaykaew ^a   Lee, Sue J ^a,f   Turner, Gareth Dh ^a,f   Dondorp, Arjen M ^a,f   Schultz, Marcus J ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Zaan Medical Centre   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^e CHITTAGONG MEDICAL COLLEGE HOSPITAL   (Bangladesh)

^f UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Acute kidney injury; Falciparum malaria; Histidine rich protein 2; Pathophysiology; Soluble urokinase type plasminogen activator receptor

Indexed keywords

BIOLOGICAL MARKER; CREATININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLASMODIUM FALCIPARUM HISTIDINE RICH PROTEIN 2; PROTEIN; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ACUTE KIDNEY FAILURE; ACUTE KIDNEY TUBULE NECROSIS; ADULT; ARTICLE; CELL ACTIVATION; CREATININE CLEARANCE; DISEASE SEVERITY; EXPLORATORY RESEARCH; FEMALE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MONONUCLEAR CELL; PARASITE LOAD; PROTEIN BLOOD LEVEL;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; ANIMALS; ANTIGENS, PROTOZOAN; BIOLOGICAL MARKERS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PARASITE LOAD; PROTOZOAN PROTEINS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; YOUNG ADULT;

EID: 84899060619     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-91     Document Type: Article

References (40)

1. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Dondorp A, Nosten F, Stepniewska K, Day NP, White NJ, South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group, Lancet 2005 366 717 725 16125588
2. Acute renal failure in patients with severe falciparum malaria. Trang TT, Phu NH, Vinh H, Hien TT, Cuong BM, Chau TT, Mai NT, Waller DJ, White NJ, Clin Infect Dis 1992 15 874 880 10.1093/clind/15.5.874 1445988
3. Predicting the clinical outcome of severe falciparum malaria in african children: findings from a large randomized trial. von Seidlein L, Olaosebikan R, Hendriksen IC, Lee SJ, Adedoyin OT, Agbenyega T, Nguah SB, Bojang K, Deen JL, Evans J, Fanello CI, Gomes E, Pedro AJ, Kahabuka C, Karema C, Kivaya E, Maitland K, Mokuolu OA, Mtove G, Mwanga-Amumpaire J, Nadjm B, Nansumba M, Ngum WP, Onyamboko MA, REyburn H, Salkulthaew T, Silamut K, Tshefu AK, Umulisa N, Gesase S, Day NP, White NJ, Dondorp AM, Clin Infect Dis 2012 54 1080 1090 10.1093/cid/cis034 22412067
4. Malaria. White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AM, Lancet 2013 383 723 735 23953767
5. Falciparum malaria associated with jaundice, renal failure and anaemia. Mukherjee AP, White JC, Lau KS, Trans R Soc Trop Med Hyg 1971 65 808 814 10.1016/0035-9203(71)90096-4 4945560
6. A quantitative ultrastructural study of renal pathology in fatal Plasmodium falciparum malaria. Nguansangiam S, Day NP, Hien TT, Mai NT, Chaisri U, Riganti M, Dondorp AM, Lee SJ, Phu NH, Turner GD, White NJ, Ferguson DJ, Pongponratn E, Trop Med Int Health 2007 12 1037 1050 10.1111/j.1365-3156.2007. 01881.x 17875015
7. Renal failure in malaria. Sitprija V, Indraprasit S, Pochanugool C, Benyajati C, Piyaratn P, Lancet 1967 1 185 188 4163125
8. Stage-dependent production and release of histidine-rich protein 2 by Plasmodium falciparum. Desakorn V, Dondorp AM, Silamut K, Pongtavornpinyo W, Sahassananda D, Chotivanich K, Pitisuttithum P, Smithyman AM, Day NP, White NJ, Trans R Soc Trop Med Hyg 2005 99 517 524 10.1016/j.trstmh.2004.11.014 15876442
9. Estimation of the total parasite biomass in acute falciparum malaria from plasma PfHRP2. Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut K, Chotivanich K, Newton PN, Pitisuttithum P, Smithyman AM, White NJ, Day NP, PLoS Med 2005 2 204 10.1371/journal.pmed.0020204 16104831
10. Diagnosing severe falciparum malaria in parasitaemic African children: a prospective evaluation of plasma PfHRP2 measurement. Hendriksen IC, Mwanga-Amumpaire J, von Seidlein L, Mtove G, White LJ, Olaosebikan R, Lee SJ, Tshefu AK, Woodrow C, Amos B, Karema C, Saiwaew S, Maitland K, Gomes E, Pan-Ngum W, Gesase S, Silamut K, Reyburn H, Joseph S, Chotivanich K, Fanello CI, Day NP, White NJ, Dondorp AM, PLoS Med 2012 9 1001297 10.1371/journal.pmed.1001297 22927801
11. Plasma Plasmodium falciparum histidine-rich protein-2 concentrations are associated with malaria severity and mortality in Tanzanian children. Rubach MP, Mukemba J, Florence S, John B, Crookston B, Lopansri BK, Yeo TW, Piera KA, Alder SC, Weinberg JB, Anstey NM, Granger DL, Mwaikambo ED, PLoS One 2012 7 35985 10.1371/journal.pone.0035985 22586457
12. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Yeo TW, Lampah DA, Gitawati R, Tjitra E, Kenangalem E, Piera K, Price RN, Duffull SB, Celermajer DS, Anstey NM, Proc Natl Acad Sci USA 2008 105 17097 17102 10.1073/pnas.0805782105 18957536
13. Serum suPAR in patients with FSGS: trash or treasure? Maas RJ, Deegens JK, Wetzels JF, Pediatr Nephrol 2013 28 1041 1048 10.1007/s00467-013-2452-5 23515666
14. Enhanced release of soluble urokinase receptor by endothelial cells in contact with peripheral blood cells. Mustjoki S, Sidenius N, Vaheri A, FEBS Lett 2000 486 237 242 10.1016/S0014-5793(00)02312-7 11119710
15. Sites of urokinase-type plasminogen activator expression and distribution of its receptor in the normal human kidney. Wagner SN, Atkinson MJ, Wagner C, Hofler H, Schmitt M, Wilhelm O, Histochem Cell Biol 1996 105 53 60 10.1007/BF01450878 8824906
16. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. Ostrowski SR, Ullum H, Goka BQ, Hoyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, Kurtzhals JA, J Infect Dis 2005 191 1331 1341 10.1086/428854 15776381
17. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Perch M, Kofoed P, Fischer TK, Co F, Rombo L, Aaby P, Eugen-Olsen J, Parasite Immunol 2004 26 207 211 10.1111/j.0141-9838.2004.00695.x 15491469
18. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, Krawczeski CD, Koyner JL, Murray P, Zappitelli M, Goldstein SL, Makris K, Ronco C, Martensson J, Martling CR, Venge P, Siew E, Ware LB, Ikizler TA, Mertens PR, J Am Coll Cardiol 2011 57 1752 1761 10.1016/j.jacc.2010.11.051 21511111
19. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P, J Am Soc Nephrol 2003 14 2534 2543 10.1097/01.ASN.0000088027.54400.C6 14514731
20. Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications. Singer E, Marko L, Paragas N, Barasch J, Dragun D, Muller DN, Budde K, Schmidt-Ott KM, Acta Physiol (Oxf) 2013 207 663 672 10.1111/apha.12054 23375078
21. N-acetylcysteine as adjunctive treatment in severe malaria: a randomized, double-blinded placebo-controlled clinical trial. Charunwatthana P, Abul Faiz M, Ruangveerayut R, Maude RJ, Rahman MR, Roberts LJ, 2nd, Moore K, Bin Yunus E, Hoque MG, Hasan MU, Lee SJ, Pukrittayakamee S, Newton PN, White NJ, Day NP, Dondorp AM, Crit Care Med 2009 37 516 522 10.1097/CCM.0b013e3181958dfd 19114891
22. Randomized controlled trial of levamisole hydrochloride as adjunctive therapy in severe falciparum malaria with high parasitemia. Maude RJ, Silamut K, Plewes K, Charunwatthana P, Ho M, Abul Faiz M, Rahman R, Hossain MA, Hassan MU, Bin Yunus E, Hoque G, Islam F, Ghose A, Hanson J, Schlatter J, Lacey R, Eastaugh A, Tarning J, Lee SJ, White NJ, Chotivanich K, Day NP, Dondorp AM, J Infect Dis 2014 209 120 129 10.1093/infdis/jit410 23943850
23. Laboratory prediction of the requirement for renal replacement in acute falciparum malaria. Hanson J, Hasan MM, Royakkers AA, Alam S, Charunwatthana P, Maude RJ, Douthwaite ST, Yunus EB, Mantha ML, Schultz MJ, Faiz MA, White NJ, Day NP, Dondorp AM, Malar J 2011 10 217 10.1186/1475-2875-10-217 21813009
24. WHO, Guidelines for the Treatment of Malaria Geneva: World Health Organization 2010 [ http://www.who.int/malaria/publications/atoz/9789241547925/ en/ ]
25. Prediction of creatinine clearance from serum creatinine. Cockcroft DW, Gault MH, Nephron 1976 16 31 41 10.1159/000180580 1244564
26. The pathophysiologic and prognostic significance of acidosis in severe adult malaria. Day NP, Phu NH, Mai NT, Chau TT, Loc PP, Chuong LV, Sinh DX, Holloway P, Hien TT, White NJ, Crit Care Med 2000 28 1833 1840 10.1097/00003246-200006000-00025 10890629
27. Acute renal failure in malaria: changing trends. Prakash J, Singh AK, Gujrati S, Maheshwari A, Indian J Nephrol 2002 12 113 117
28. Acute renal failure in falciparum malaria. Segasothy M, Swaminathan M, Kong NC, Med J Malaysia 1994 49 412 415 7674979
29. Effects of dopamine and epinephrine infusions on renal hemodynamics in severe malaria and severe sepsis. Day NP, Phu NH, Mai NT, Bethell DB, Chau TT, Loc PP, Chuong LV, Sinh DX, Solomon T, Haywood G, Hien TT, White NJ, Crit Care Med 2000 28 1353 1362 10.1097/00003246-200005000-00016 10834678
30. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F, Crit Care 2011 15 63 10.1186/cc10037 21324198
31. Serum-soluble urokinase receptor concentration in primary FSGS. Maas RJ, Wetzels JF, Deegens JK, Kidney Intl 2012 81 1043 1044
32. Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute Puumala hantavirus infection. Outinen TK, Tervo L, Makela S, Huttunen R, Maenpaa N, Huhtala H, Vaheri A, Mustonen J, Aittoniemi J, PLoS One 2013 8 71335 10.1371/journal.pone.0071335 23990945
33. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis? Pawlak K, Ulazka B, Mysliwiec M, Pawlak D, Transl Res 2012 160 346 354 22683425
34. Lesion associated expression of urokinase-type plasminogen activator receptor (uPAR, CD87) in human cerebral malaria. Fauser S, Deininger MH, Kremsner PG, Magdolen V, Luther T, Meyermann R, Schluesener HJ, J Neuroimmunol 2000 111 234 240 10.1016/S0165-5728(00)00368-4 11063844
35. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Pliyev BK, Mol Cell Biochem 2009 321 111 122 10.1007/s11010-008-9925-z 18830568
36. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F, EMBO J 1996 15 1572 1582 8612581
37. Tumour necrosis factor production in falciparum malaria and its association with schizont rupture. Kwiatkowski D, Cannon JG, Manogue KR, Cerami A, Dinarello CA, Greenwood BM, Clin Exp Immunol 1989 77 361 366 2680183
38. Haemozoin induces early cytokine-mediated lysozyme release from human monocytes through p38 MAPK- and NF-kappaB-dependent mechanisms. Polimeni M, Valente E, Aldieri E, Khadjavi A, Giribaldi G, Prato M, PLoS One 2012 7 39497 10.1371/journal.pone.0039497 22724024
39. suPAR: the molecular crystal ball. Thuno M, Macho B, Eugen-Olsen J, Dis Markers 2009 27 157 172 10.1155/2009/504294 19893210
40. Biomarkers and creatinine in AKI: the trough of disillusionment or the slope of enlightenment? Endre ZH, Pickering JW, Kidney Intl 2013 84 644 647 10.1038/ki.2013.168